Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters—An in Silico Modeling Approach

Cholestasis represents one out of three types of drug induced liver injury (DILI), which comprises a major challenge in drug development. In this study we applied a two-class classification scheme based on k-nearest neighbors in order to predict cholestasis, using a set of 93 two-dimensional (2D) physicochemical descriptors and predictions of selected hepatic transporters’ inhibition (BSEP, BCRP, P-gp, OATP1B1, and OATP1B3). In order to assess the potential contribution of transporter inhibition, we compared whether the inclusion of the transporters’ inhibition predictions contributes to a significant increase in model performance in comparison to the plain use of the 93 2D physicochemical descriptors. Our findings were in agreement with literature findings, indicating a contribution not only from BSEP inhibition but a rather synergistic effect deriving from the whole set of transporters. The final optimal model was validated via both 10-fold cross validation and external validation. It performs quite satisfactorily resulting in 0.686 ± 0.013 for accuracy and 0.722 ± 0.014 for area under the receiver operating characteristic curve (AUC) for 10-fold cross-validation (mean ± standard deviation from 50 iterations).

[1]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[2]  M. Roma,et al.  Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects. , 2008, Clinical science.

[3]  K. Brouwer,et al.  Risk Factors for Development of Cholestatic Drug-Induced Liver Injury: Inhibition of Hepatic Basolateral Bile Acid Transporters Multidrug Resistance-Associated Proteins 3 and 4 , 2014, Drug Metabolism and Disposition.

[4]  E. Russo,et al.  Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two “challenging” case reports , 2013, Journal of pharmacology & pharmacotherapeutics.

[5]  Sander B Nabuurs,et al.  In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  K. Faber,et al.  Drug transport proteins in the liver. , 2003, Advanced drug delivery reviews.

[7]  T. Horie,et al.  Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. , 2011, Biochemical and biophysical research communications.

[8]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[9]  Stefan Kramer,et al.  A Large‐Scale Empirical Evaluation of Cross‐Validation and External Test Set Validation in (Q)SAR , 2013, Molecular informatics.

[10]  Dragos Horvath,et al.  Prediction of drug induced liver injury using molecular and biological descriptors. , 2015, Combinatorial chemistry & high throughput screening.

[11]  J. Guo,et al.  Risk of Hepatotoxicity Associated with the Use of Telithromycin: A Signal Detection Using Data Mining Algorithms , 2008, The Annals of pharmacotherapy.

[12]  George Kollias,et al.  Ligand-based virtual screening procedure for the prediction and the identification of novel β-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. , 2011, European journal of medicinal chemistry.

[13]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.

[14]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[15]  K. Kuchler,et al.  Flagging Drugs That Inhibit the Bile Salt Export Pump. , 2016, Molecular pharmaceutics.

[16]  N. Kawada,et al.  [Drug-induced cholestasis]. , 1995, Ryoikibetsu shokogun shirizu.

[17]  Emese Kis,et al.  BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  Yoav Freund,et al.  Experiments with a New Boosting Algorithm , 1996, ICML.

[19]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[20]  Leo Breiman,et al.  Bagging Predictors , 1996, Machine Learning.

[21]  A. Mottino,et al.  Dynamic localization of hepatocellular transporters in health and disease. , 2008, World journal of gastroenterology.

[22]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[23]  Alexander Amberg,et al.  Computational Models for Human and Animal Hepatotoxicity with a Global Application Scope. , 2016, Chemical research in toxicology.

[24]  B. Hagenbuch,et al.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.

[25]  M. Trauner,et al.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.

[26]  A. Tropsha,et al.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. , 2013, Journal of pharmaceutical sciences.

[27]  Louis-David Cantin,et al.  Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification , 2012, Drug Metabolism and Disposition.

[28]  Yuichi Sugiyama,et al.  Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs , 2006, Drug Metabolism and Disposition.

[29]  Sean Ekins,et al.  Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.

[30]  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.

[31]  Richard J. Thompson,et al.  The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.

[32]  George Kollias,et al.  In Silico Exploration for Identifying Structure–Activity Relationship of MEK Inhibition and Oral Bioavailability for Isothiazole Derivatives , 2010, Chemical biology & drug design.

[33]  Ivan Rusyn,et al.  Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method. , 2010, Chemical research in toxicology.

[34]  O. Fardel,et al.  The drug efflux pump MRP2: Regulation of expression in physiopathological situations and by endogenous and exogenous compounds , 2004, Cell Biology and Toxicology.

[35]  Stefan Brenner,et al.  Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models , 2015, Molecular pharmaceutics.

[36]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[37]  Hugh A. Barton,et al.  Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..

[38]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[39]  Xiao Fu,et al.  A Liver-Centric Multiscale Modeling Framework for Xenobiotics , 2016, PloS one.

[40]  Gerd A. Kullak-Ublick,et al.  Drug-Induced Cholestatic Liver Disease , 2013 .

[41]  C. Bénichou Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[42]  W. Alrefai,et al.  Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications , 2007, Pharmaceutical Research.

[43]  Alexander Golbraikh,et al.  A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..

[44]  M. Vihinen How to evaluate performance of prediction methods? Measures and their interpretation in variation effect analysis , 2012, BMC Genomics.

[45]  K. Kuchler,et al.  Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P‐Glycoprotein (P‐gp) and Breast Cancer Resistance Protein (BCRP) , 2016, ChemMedChem.

[46]  P. Watkins,et al.  Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI , 2014, CPT: pharmacometrics & systems pharmacology.

[47]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[48]  Weida Tong,et al.  Toward predictive models for drug-induced liver injury in humans: are we there yet? , 2014, Biomarkers in medicine.

[49]  Arie Regev,et al.  Drug-Induced Liver Injury and Drug Development: Industry Perspective , 2014, Seminars in Liver Disease.

[50]  J. Friedman Special Invited Paper-Additive logistic regression: A statistical view of boosting , 2000 .

[51]  F. Russel,et al.  In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. , 2014, Chemical research in toxicology.

[52]  Ferran Sanz,et al.  eTOXlab, an open source modeling framework for implementing predictive models in production environments , 2015, Journal of Cheminformatics.

[53]  S. Erlinger NTCP deficiency: a new inherited disease of bile acid transport. , 2015, Clinics and research in hepatology and gastroenterology.

[54]  Pedro M. Domingos MetaCost: a general method for making classifiers cost-sensitive , 1999, KDD '99.

[55]  Paul B Watkins,et al.  Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.

[56]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[57]  Manfred Hauben,et al.  Early Postmarketing Drug Safety Surveillance: Data Mining Points to Consider , 2004, The Annals of pharmacotherapy.

[58]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[59]  P. Meier,et al.  Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.

[60]  Maarten L J Coonen,et al.  Classification of hepatotoxicants using HepG2 cells: A proof of principle study. , 2014, Chemical research in toxicology.

[61]  F. Ballet,et al.  Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.

[62]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[63]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[64]  Naomi L Kruhlak,et al.  Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data. , 2014, Toxicology.

[65]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[66]  J. VandeBerg,et al.  Hepatobiliary transport in health and disease , 2012, Clinical lipidology.